Takeda licenses 2 drugs to NPS for as much as $80M

03/20/2013 | Genetic Engineering & Biotechnology News

Takeda Pharmaceutical granted NPS Pharmaceuticals complete global rights to develop and market its adult short bowel syndrome drug teduglutide and recombinant human parathyroid hormone 1-84, which is approved in Europe for post-menopausal osteoporosis. The deal covers all assets related to the two products. NPS will pay Takeda $50 million in common stock and a potential $30 million milestone fee.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX